by epivax3 | Aug 3, 2017 | EpiVax Immunoncology, News, Thinking Out Loud -Blog
Accelerating the Development of a Game Changing Cancer Therapy PROVIDENCE, R.I., Aug. 3, 2017 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) today announced it received funding from the Rhode Island Commerce Corporation to accelerate the development of...
by epivax3 | Mar 19, 2013 | Events
Dr. Annie De Groot will be in Japan from May 8th – 15th, to meet with collaborators and host a semi-annual seminar on immunogenicity. Please see below for details. Sign Up Here! (フォームを登録) – PDF Agenda (議題) Immunogenicity Seminar 2013 Sponsored by: The...
by epivax3 | Oct 8, 2010 | News
Annie De Groot [class of] ’78 is using mathematical models and cutting-edge computer science to map the body’s response to disease. Her goal is to eradicate some of the world’s deadliest illnesses by making vaccines—and health care— available to everyone. Read the...
by epivax3 | Oct 6, 2010 | News
This year, EpiVax was awarded $243,561 in Total Direct and Indirect Funding to support the development of their unique HIV vaccine platform (de-tolerized anti-Dec205). The total amount awarded to date is $797,855 in Direct and Indirect costs, to further this aspect of...
by epivax3 | Sep 28, 2010 | News
PROVIDENCE, R.I. – September 21, 2010 – Adding to a $13 million grant awarded to her Institute for Immunology and Informatics last summer, EpiVax CEO Annie De Groot has received an additional $511,121 from the National Institutes of Health to expand the use of...
